Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease
✍ Scribed by Avigayil Ribner; Gheona Altarescu; Ari Zimran; Deborah Elstein
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 486 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background:
There is an increased incidence of Parkinson's disease among obligate carriers of the common glucocerebrosidase mutations, and among patients with Parkinson disease there is an increased number who are carriers of glucocerebrosidase mutations. A Gaucher mutation is considered a susceptibility factor for Parkinson's disease. Osteopontin single‐nucleotide polymorphism–66 is associated with Lewy body disease and considered a susceptibility factor. The aim of this study was to ascertain whether Gaucher patients with parkinsonism carry the osteopontin single‐nucleotide polymorphism‐66 polymorphic genotype TT to a greater extent than other Gaucher patients.
Methods:
Seventy adult patients with at least 1 allele having the common N370S Gaucher mutation including 10 patients with Parkinson's disease were included.
Results:
There was no statistically significant difference in incidence of the TT genotype in patients with clinically symptomatic Parkinson's disease (88.9%) and other Gaucher patients (72.1%).
Conclusions:
This may partly explain the increased incidence of Parkinson's disease associated with Gaucher mutations. © 2011 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract Our objective was to assess the association between risk factors for Parkinson's disease (PD) and abnormal olfaction in first‐degree relatives of patients with PD. Factors including lower cigarette smoking and lower caffeine consumption have been associated with increased risk of PD. Id
## Abstract It has been suggested that use of nonsteroidal anti‐inflammatory drugs (NSAID) protects against Parkinson's disease, although the results are not consistent. We investigated the risk for Parkinson's disease in patients with osteoarthritis, who are typically intensive users of NSAID. By
## Abstract We studied two genetic polymorphisms (240C/T and 480G/A) of the brain‐derived neurotrophic factor (BDNF) gene in Japanese patients with Alzheimer's disease (AD, n = 172), Parkinson's disease (PD, n = 327), and multiple system atrophy (MSA, n = 122), as well as controls (n = 275). The di
## Abstract Because methamphetamine exposure to experimental animals can damage brain dopamine neurones, we examined whether hospital patients diagnosed with methamphetamine‐related disorders might have greater risk of subsequent admission with a Parkinson's disease diagnosis. This was a population
## Abstract Impaired debrisoquine metabolism resulting from defects in the cytochrome P450 __CYP2D6__‐debrisoquine hydroxylase gene has been shown to be associated with the development of Parkinson's disease(PD). We studied two polymorphisms in this gene in 207 Chinese PD patients and 227 control s